OmniAb, Inc.
NASDAQ:OABIBiotechnology
+$0.16 today
- Market cap
- $740.97M
- Beta
- 1.15
- P/E (TTM)
- -5.2
- EPS (TTM)
- -$0.42
Volume 1.22M
Average 0.67M
OABI Selling, General & Admin
Overhead costs of running the business, including sales, marketing, management, and administrative staff.
OmniAb, Inc.NASDAQ: OABI
Selling, General & Admin · Q1 FY2026 · quarter ended Mar 2026
Selling, general & admin declines year over year
Q1 FY2026 selling, general & admin of $6.6M fell 16.6% year over year, behind the -12.7% change in trailing-twelve-month selling, general & admin. Sequentially, it fell 3.5% from the prior quarter. Over 3 fiscal years it compounded at +5.5% a year.
Context
- Selling, general & admin amounted to 156.5% of revenue in FY2025, up 40.0 pp from a year earlier.
- Selling, general & admin increased in 1 of the last 3 fiscal years.
What to watch
Whether selling, general & admin reaches the consensus estimate from 5 analysts of $34.08M (+16.7%) for the fiscal year ending Dec 2026, a step up from the -5.0% reported in FY2025.
Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterMar 2026
- $6.6M-3.5% QoQ
- Last fiscal yearDec 2025
- $29.22M-5.0% YoY
- LTMMar 2026
- $26.47M-12.7% YoY
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
Selling, General & Admin history
USD · from the income statement
- Latest · FY2025
- 29.22M USD
- Year-over-year change
- -5.0%
- 4-year CAGR
- +14.6%
| Period | Period end | Selling, General & Admin | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 29.22M | -5.0% |
| FY2024 | 2024-12-31 | 30.74M | -7.7% |
| FY2023 | 2023-12-31 | 33.31M | +33.8% |
| FY2022 | 2022-12-31 | 24.9M | +46.9% |
| FY2021 | 2021-12-31 | 16.95M | — |
Selling, General & Admin vs competitors
How OABI compares with its peers on the latest reported figures
- OABI's LTM Mar 2026 selling, general & admin of $26.47M is the 3rd highest of the 4 companies compared; the peer median is $35.33M.
- Its year-over-year change of -12.7% is the 2nd highest of 4, against a peer median of -27.9%.
- Selling, general & admin amounts to 91.6% of revenue for OABI, versus a peer median of 35.5%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $38.15M | -27.9% | -12.7% | 24.3% | |
| LTM Mar 2026 | $35.33M | -27.9% | -11.7% | 35.5% | |
| LTM Mar 2026 | $26.47M | -12.7% | +5.5% | 91.6% | |
| LTM Mar 2026 | $17.68M | +91.0% | — | 962.7% | |
VRXAVeraxa Biotech Holding AG | — | — | — | — | — |
| Peer median (excluding OABI) | $35.33M | -27.9% | -12.2% | 35.5% | |
Competitors are the stored peer set for OABI. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 34.75M | 59.08M | 34.16M | 26.39M | 18.67M |
| Cost of Revenue | 0 | 0 | 0 | 0 | 22.06M |
| Gross Profit | 34.75M | 59.08M | 34.16M | 26.39M | (3.39M) |
| Gross Margin | 100.0% | 100.0% | 100.0% | 100.0% | -18.2% |
| Research & Development | 39.23M | 48.36M | 56.53M | 55.11M | 47.75M |
| Selling, General & Admin | 16.95M | 24.9M | 33.31M | 30.74M | 29.22M |
| Operating Expenses | 70.36M | 85.73M | 103.58M | 100.89M | 68.13M |
| Depreciation & Amortization | 16.25M | 18.25M | 19.5M | 23.58M | 21.75M |
| EBITDA | (18.09M) | (7.81M) | (44.87M) | (47.83M) | (44.54M) |
| EBITDA Margin | -52.1% | -13.2% | -131.3% | -181.2% | -238.6% |
| Operating Income | (35.61M) | (26.65M) | (69.42M) | (74.5M) | (71.52M) |
| Operating Margin | -102.5% | -45.1% | -203.2% | -282.3% | -383.1% |
| Interest Income | 0 | 587K | 5.06M | 3.11M | 2.66M |
| Interest Expense | 7K | 0 | 0 | 0 | 0 |
| Other Income / Expenses | 1.26M | 587K | 5.06M | 3.09M | 5.22M |
| Income Before Tax | (34.35M) | (26.06M) | (64.36M) | (71.41M) | (66.29M) |
| Pre-Tax Margin | -98.9% | -44.1% | -188.4% | -270.6% | -355.2% |
| Income Tax Expense | (7.31M) | (3.73M) | (13.74M) | (9.38M) | (1.52M) |
| Net Income | (27.04M) | (22.33M) | (50.62M) | (62.03M) | (64.78M) |
| Net Margin | -77.8% | -37.8% | -148.2% | -235.1% | -347.0% |
| EPS (Basic) | (0.24) | (0.26) | (0.51) | (0.61) | (0.57) |
| EPS (Diluted) | (0.24) | (0.26) | (0.51) | (0.61) | (0.57) |
| Weighted Avg Shares | 114.82M | 85.32M | 99.68M | 102.37M | 113.64M |
| Weighted Avg Shares (Diluted) | 114.82M | 85.32M | 99.68M | 102.37M | 113.64M |
OmniAb, Inc.
NASDAQ:OABI
Intrinsic Alpha fair value
Locked
Current Price
$5.08
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.